Agilent Technologies, Inc. (0HAV.L)
USD 136.25
(-0.67%)
USD 136.25
(-0.67%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 10.76 Billion USD | 2.35% |
| 2022 | 10.51 Billion USD | -1.77% |
| 2021 | 10.7 Billion USD | 11.2% |
| 2020 | 9.62 Billion USD | 1.85% |
| 2019 | 9.45 Billion USD | 10.67% |
| 2018 | 8.54 Billion USD | 1.33% |
| 2017 | 8.42 Billion USD | 7.83% |
| 2016 | 7.81 Billion USD | 4.56% |
| 2015 | 7.47 Billion USD | -30.52% |
| 2014 | 10.76 Billion USD | 0.69% |
| 2013 | 10.68 Billion USD | 1.42% |
| 2012 | 10.53 Billion USD | 16.33% |
| 2011 | 9.05 Billion USD | -6.09% |
| 2010 | 9.64 Billion USD | 26.69% |
| 2009 | 7.61 Billion USD | 2.35% |
| 2008 | 7.43 Billion USD | -1.55% |
| 2007 | 7.55 Billion USD | 2.51% |
| 2006 | 7.36 Billion USD | 9.15% |
| 2005 | 6.75 Billion USD | -4.32% |
| 2004 | 7.05 Billion USD | 12.05% |
| 2003 | 6.29 Billion USD | -23.24% |
| 2002 | 8.2 Billion USD | 2.72% |
| 2001 | 7.98 Billion USD | -5.21% |
| 2000 | 8.42 Billion USD | 54.76% |
| 1999 | 5.44 Billion USD | 9.16% |
| 1998 | 4.98 Billion USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 10.85 Billion USD | -0.84% |
| 2024 Q1 | 10.94 Billion USD | 1.72% |
| 2024 Q3 | 10.99 Billion USD | 1.29% |
| 2023 Q2 | 10.79 Billion USD | -1.16% |
| 2023 Q4 | 10.76 Billion USD | 0.82% |
| 2023 Q3 | 10.67 Billion USD | -1.08% |
| 2023 Q1 | 10.91 Billion USD | 3.83% |
| 2023 FY | 10.76 Billion USD | 2.35% |
| 2022 Q3 | 10.48 Billion USD | 0.28% |
| 2022 Q4 | 10.51 Billion USD | 0.31% |
| 2022 FY | 10.51 Billion USD | -1.77% |
| 2022 Q1 | 10.32 Billion USD | -3.53% |
| 2022 Q2 | 10.45 Billion USD | 1.24% |
| 2021 Q2 | 10.39 Billion USD | 7.48% |
| 2021 Q1 | 9.67 Billion USD | 0.49% |
| 2021 FY | 10.7 Billion USD | 11.2% |
| 2021 Q4 | 10.7 Billion USD | 2.04% |
| 2021 Q3 | 10.49 Billion USD | 0.89% |
| 2020 Q1 | 9.5 Billion USD | 0.52% |
| 2020 Q2 | 9.45 Billion USD | -0.48% |
| 2020 Q3 | 9.54 Billion USD | 0.96% |
| 2020 Q4 | 9.62 Billion USD | 0.85% |
| 2020 FY | 9.62 Billion USD | 1.85% |
| 2019 FY | 9.45 Billion USD | 10.67% |
| 2019 Q4 | 9.45 Billion USD | 9.59% |
| 2019 Q1 | 8.95 Billion USD | 4.81% |
| 2019 Q2 | 9.02 Billion USD | 0.78% |
| 2019 Q3 | 8.62 Billion USD | -4.4% |
| 2018 Q3 | 8.34 Billion USD | -4.95% |
| 2018 FY | 8.54 Billion USD | 1.33% |
| 2018 Q1 | 8.69 Billion USD | 3.19% |
| 2018 Q2 | 8.78 Billion USD | 0.99% |
| 2018 Q4 | 8.54 Billion USD | 2.3% |
| 2017 FY | 8.42 Billion USD | 7.83% |
| 2017 Q3 | 8.26 Billion USD | 3.06% |
| 2017 Q2 | 8.01 Billion USD | 1.83% |
| 2017 Q1 | 7.87 Billion USD | 0.7% |
| 2017 Q4 | 8.42 Billion USD | 2.03% |
| 2016 Q2 | 7.64 Billion USD | 4.63% |
| 2016 FY | 7.81 Billion USD | 4.56% |
| 2016 Q1 | 7.3 Billion USD | -2.33% |
| 2016 Q4 | 7.81 Billion USD | 1.07% |
| 2016 Q3 | 7.73 Billion USD | 1.23% |
| 2015 Q3 | 7.25 Billion USD | -2.17% |
| 2015 Q1 | 7.51 Billion USD | -30.12% |
| 2015 Q4 | 7.47 Billion USD | 3.1% |
| 2015 FY | 7.47 Billion USD | -30.52% |
| 2015 Q2 | 7.41 Billion USD | -1.42% |
| 2014 FY | 10.76 Billion USD | 0.69% |
| 2014 Q1 | 10.63 Billion USD | -0.45% |
| 2014 Q4 | 10.76 Billion USD | 3.66% |
| 2014 Q3 | 10.38 Billion USD | -5.86% |
| 2014 Q2 | 11.02 Billion USD | 3.65% |
| 2013 FY | 10.68 Billion USD | 1.42% |
| 2013 Q4 | 10.68 Billion USD | 3.97% |
| 2013 Q1 | 10.65 Billion USD | 1.11% |
| 2013 Q2 | 10.58 Billion USD | -0.62% |
| 2013 Q3 | 10.27 Billion USD | -2.92% |
| 2012 Q2 | 9.41 Billion USD | 3.45% |
| 2012 FY | 10.53 Billion USD | 16.33% |
| 2012 Q4 | 10.53 Billion USD | 7.98% |
| 2012 Q3 | 9.75 Billion USD | 3.65% |
| 2012 Q1 | 9.09 Billion USD | 0.46% |
| 2011 FY | 9.05 Billion USD | -6.09% |
| 2011 Q4 | 9.05 Billion USD | 3.47% |
| 2011 Q3 | 8.75 Billion USD | 1.2% |
| 2011 Q2 | 8.64 Billion USD | 7.52% |
| 2011 Q1 | 8.04 Billion USD | -17.04% |
| 2010 FY | 9.64 Billion USD | 26.69% |
| 2010 Q3 | 9.1 Billion USD | 17.16% |
| 2010 Q2 | 7.76 Billion USD | 2.21% |
| 2010 Q1 | 7.59 Billion USD | -0.17% |
| 2010 Q4 | 9.69 Billion USD | 6.55% |
| 2009 Q2 | 6.57 Billion USD | -8.18% |
| 2009 Q1 | 7.16 Billion USD | -3.7% |
| 2009 FY | 7.61 Billion USD | 2.35% |
| 2009 Q3 | 6.57 Billion USD | -0.05% |
| 2009 Q4 | 7.61 Billion USD | 15.81% |
| 2008 Q3 | 7.54 Billion USD | -1.73% |
| 2008 Q2 | 7.67 Billion USD | 2.88% |
| 2008 FY | 7.43 Billion USD | -1.55% |
| 2008 Q4 | 7.43 Billion USD | -1.38% |
| 2008 Q1 | 7.45 Billion USD | -1.26% |
| 2007 Q2 | 7.28 Billion USD | 1.25% |
| 2007 Q4 | 7.55 Billion USD | 7.55% |
| 2007 FY | 7.55 Billion USD | 2.51% |
| 2007 Q1 | 7.19 Billion USD | -2.39% |
| 2007 Q3 | 7.02 Billion USD | -3.56% |
| 2006 Q1 | 8.02 Billion USD | 18.89% |
| 2006 FY | 7.36 Billion USD | 9.15% |
| 2006 Q4 | 7.36 Billion USD | -4.66% |
| 2006 Q3 | 7.72 Billion USD | -4.07% |
| 2006 Q2 | 8.05 Billion USD | 0.39% |
| 2005 Q3 | 7.35 Billion USD | 1.16% |
| 2005 Q4 | 6.75 Billion USD | -8.17% |
| 2005 Q1 | 7.15 Billion USD | 1.33% |
| 2005 Q2 | 7.26 Billion USD | 1.65% |
| 2005 FY | 6.75 Billion USD | -4.32% |
| 2004 Q2 | 6.67 Billion USD | 4.56% |
| 2004 Q1 | 6.38 Billion USD | 1.38% |
| 2004 FY | 7.05 Billion USD | 12.05% |
| 2004 Q3 | 6.74 Billion USD | 0.99% |
| 2004 Q4 | 7.05 Billion USD | 4.67% |
| 2003 FY | 6.29 Billion USD | -23.24% |
| 2003 Q4 | 6.29 Billion USD | 5.13% |
| 2003 Q3 | 5.99 Billion USD | -21.36% |
| 2003 Q1 | 7.77 Billion USD | -5.28% |
| 2003 Q2 | 7.61 Billion USD | -1.97% |
| 2002 Q2 | 8.23 Billion USD | -3.74% |
| 2002 Q3 | 8.43 Billion USD | 2.42% |
| 2002 Q4 | 8.2 Billion USD | -2.77% |
| 2002 FY | 8.2 Billion USD | 2.72% |
| 2002 Q1 | 8.55 Billion USD | 7.16% |
| 2001 Q4 | 7.98 Billion USD | -7.38% |
| 2001 Q3 | 8.62 Billion USD | -5.04% |
| 2001 Q2 | 9.08 Billion USD | -1.39% |
| 2001 FY | 7.98 Billion USD | -5.21% |
| 2001 Q1 | 9.2 Billion USD | 9.29% |
| 2000 Q1 | 7.1 Billion USD | 30.55% |
| 2000 Q2 | 7.32 Billion USD | 3.01% |
| 2000 Q3 | 7.82 Billion USD | 6.91% |
| 2000 FY | 8.42 Billion USD | 54.76% |
| 2000 Q4 | 8.42 Billion USD | 7.64% |
| 1999 Q4 | 5.44 Billion USD | 0.0% |
| 1999 FY | 5.44 Billion USD | 9.16% |
| 1998 FY | 4.98 Billion USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | -2056.253% |
| Dynavax Technologies Corporation | 997.09 Million USD | -979.435% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -663.888% |
| Perrigo Company plc | 10.8 Billion USD | 0.426% |
| Illumina, Inc. | 10.11 Billion USD | -6.448% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 89.098% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -1279.251% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 86.718% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 59.66% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -4737.173% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 67.464% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -16284.533% |
| Waters Corporation | 4.62 Billion USD | -132.62% |
| Biogen Inc. | 26.84 Billion USD | 59.907% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -6410.404% |
| Evolus, Inc. | 188.99 Million USD | -5594.769% |
| Adicet Bio, Inc. | 207.29 Million USD | -5092.118% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -8452.652% |
| bluebird bio, Inc. | 619.16 Million USD | -1638.32% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -5129.936% |
| FibroGen, Inc. | 423.52 Million USD | -2441.266% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -37968.939% |
| Homology Medicines, Inc. | 47.05 Million USD | -22772.261% |
| Geron Corporation | 394.07 Million USD | -2631.199% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -181.027% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -1283.632% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -797.889% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -2820.839% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -727.301% |
| Zoetis Inc. | 14.28 Billion USD | 24.661% |
| Abeona Therapeutics Inc. | 64 Million USD | -16716.662% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | -220.752% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | -57.317% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 52.649% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -19137.162% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -259.958% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -6403.166% |
| Verastem, Inc. | 149.71 Million USD | -7088.848% |
| Nektar Therapeutics | 398.03 Million USD | -2604.047% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -1729.708% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -5352.243% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -229.691% |
| OPKO Health, Inc. | 2.01 Billion USD | -435.021% |
| Exelixis, Inc. | 2.94 Billion USD | -265.795% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -231.027% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -1631.731% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -6871.487% |
| uniQure N.V. | 831.68 Million USD | -1194.114% |
| Imunon, Inc. | 21.91 Million USD | -49005.603% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -925.78% |
| Insmed Incorporated | 1.32 Billion USD | -709.347% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -520.965% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -1048.521% |
| TG Therapeutics, Inc. | 329.58 Million USD | -3165.602% |
| Incyte Corporation | 6.78 Billion USD | -58.697% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -486.571% |